SIGA Technologies Inc Dossier
Qualitative Analysis
Business overview
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market, specializing in medical countermeasures for biological, chemical, radiological, and nuclear (CBRN) threats, as well as emerging infectious diseases. The company's lead product is TPOXX® (tecovirimat), an antiviral drug approved for the treatment of human smallpox disease caused by the variola virus. TPOXX is available in both oral and intravenous (IV) formulations. SIGA's business model is heavily anchored in government procurement contracts, particularly with U.S. federal agencies such as the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense (DoD), which maintain stockpiles of TPOXX in the Strategic National Stockpile (SNS). Additionally, the company is expanding its international footprint, securing procurement orders and regulatory approvals globally, and is actively evaluating TPOXX for broader orthopoxvirus indications, including mpox.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of an oral liquid suspension formulation of TPOXX designed for pediatric patients weighing less than 13kg who cannot swallow capsules.
Expected impact: Expands the addressable patient population and strengthens TPOXX's role in biothreat preparedness.
Expanding the regulatory label of TPOXX to include post-exposure prophylaxis, allowing administration to individuals after exposure to smallpox but before symptoms appear.
Expected impact: Significantly broadens the clinical utility of TPOXX, potentially increasing government stockpile sizes and per-unit value.
Direct commercial push to expand the international footprint of TPOXX, transitioning away from the Meridian promotion agreement expiring in May 2026.
Expected impact: Reduces long-term dependence on U.S. government procurement cycles by capturing global stockpiling demand.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Hikma exclusive rights to register and commercialize oral TPOXX across the Middle East and North Africa (MENA) region, unlocking demand in a historically underrepresented market for SIGA.
Terms: SIGA will act as the sole manufacturer and supply finished product to Hikma at a set price. SIGA may also be entitled to additional payments under certain conditions; specific financial terms remain confidential.